Arcus Biosciences, Inc. SEC Filings

Arcus Biosciences Chief Executive Officer and director Terry J. Rosen reported a charitable gift of company stock. On 01/08/2026, Rosen donated 35,000 shares of Arcus Biosciences, Inc. common stock, coded as a charitable gift transaction. The shares were transferred at a reported price of $0 per share, consistent with a non-cash donation. After this gift, Rosen beneficially owned 2,157,409 shares of common stock, which the disclosure notes includes the unvested portion of his restricted stock unit grants. This filing updates the market on Rosen’s current direct equity stake in the company.

BlackRock, Inc. reports beneficial ownership of 12,736,927 shares of Arcus Biosciences common stock, representing 10.4% of the outstanding class as of the event date. BlackRock has sole voting power over 12,575,912 shares and sole dispositive power over 12,736,927 shares, with no shared voting or dispositive power.

The filing states that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of Arcus Biosciences’ common shares. BlackRock certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.

Arcus Biosciences president Juan C. Jaen reported indirect sales of Arcus Biosciences common stock held by a trust associated with him. On January 5, 2026, the trust sold 29,670 shares at a weighted average price of $21.34, 2,053 shares at a weighted average price of $22.34, and 100 shares at $23.20, under a Rule 10b5-1 trading plan adopted on August 8, 2025.

Following these transactions, the trust continued to hold 922,240 shares of Arcus Biosciences common stock. Jaen also reported 346,012 shares held directly, which include the unvested portion of his restricted stock unit grants.

A trust associated with RCUS stock filed a Rule 144 notice to sell 31,823 shares of Class A common stock through Goldman Sachs & Co. LLC on approximately 01/05/2026. The shares have an aggregate market value of $692,786.71, compared with 122,856,086 shares of this class reported as outstanding. The shares were originally acquired from the issuer in a private transaction on 05/08/2015 for full cash payment. The same trust has sold Class A common stock in prior months, including 44,950 shares on 11/17/2025 for gross proceeds of $913,028.90 and 50,000 shares on 12/04/2025 for $1,230,350.00.

Arcus Biosciences, Inc. Chief Financial Officer reported a sale of company stock in a routine insider transaction. On 12/31/2025, the reporting person sold 6,552 shares of Arcus Biosciences common stock at a price of $23.38 per share. After this transaction, the insider beneficially owned 67,924 shares of common stock in the company.

The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to a predetermined schedule, helping separate trading decisions from day-to-day nonpublic information about the business.

Arcus Biosciences, Inc. reported an insider share transfer by its Chief Executive Officer and director. On 12/30/2025, the reporting person transferred 2,400 shares of common stock at a reported price of $0, using transaction code G. After this transaction, the individual directly beneficially owns 2,192,409 shares of Arcus common stock.

According to the notes, the 2,400 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, while retaining voting and dispositive power over all of the transferred shares.

Arcus Biosciences Inc. has a notice of proposed sale under Rule 144 for 6,552 shares of common stock, to be sold through Merrill Lynch on the NYSE around 12/31/2025, with an aggregate market value of $153,185.76. Common shares outstanding were 107,973,536.

The seller, Robert C. Goeltz II, acquired these 6,552 shares on 12/15/2025 as a restricted stock unit grant from Arcus Biosciences, recorded as equity compensation. Over the prior three months, he reported multiple sales of common stock: 5,000 shares on 10/28/2025 for $100,000, 5,000 shares on 11/26/2025 for $125,000, 6,702 shares on 12/16/2025 for $146,668.58, and 5,960 shares on 12/17/2025 for $132,070.62.

Arcus Biosciences, Inc. reported that its general counsel sold company stock in mid-December 2025 in transactions related to restricted stock unit (RSU) vesting. On December 16, 2025, 7,658 shares of common stock were sold at a weighted average price of $21.8843, leaving 131,544 shares beneficially owned afterward. On December 17, 2025, a further 6,810 shares were sold at a weighted average price of $22.1595, resulting in 124,734 shares beneficially owned. The filing explains that these sales were made by the issuer on the reporting person’s behalf to cover tax withholding obligations triggered by RSU vesting under an equity administration policy implemented on May 22, 2025, and are described as non‑discretionary trades. The remaining holdings include one share acquired through the company’s employee stock purchase plan and the unvested portion of the reporting person’s RSU grants.

Arcus Biosciences Chief Medical Officer reports automatic share sales and corrects equity award vesting terms. On 12/16/2025 and 12/17/2025, the CMO sold 5,052 and 4,494 shares of common stock, respectively, as reported sales to cover tax withholding obligations tied to vesting restricted stock units. The filing states these sales occurred automatically under the company’s equity administration policy and were not discretionary trades. After these transactions, the CMO beneficially owned 70,141 and then 65,647 shares, including unvested RSUs. The document also corrects the vesting schedule for awards granted on February 10, 2025: RSUs vest in four equal annual installments beginning December 15, 2025, and stock options become exercisable in 48 equal monthly installments after January 31, 2025, subject to continued service.